Acrux Limited (AU:ACR) has released an update.
Acrux Limited has successfully launched Dapsone Gel, 5% for acne treatment in the US market and secured a $1.487 million funding facility for R&D from Radium Capital, signaling positive cashflow in recent quarters. The company is progressing with FDA reviews for three ANDAs and manufacturing for two new product launches, highlighting a strategy focused on expanding its portfolio of topically applied pharmaceuticals to ensure sustained revenue growth.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.
